Top

Current Urology Reports

Published in:

01-01-2019 | Nephrectomy | Kidney Diseases (G Ciancio, Section Editor)

Renal Medullary Carcinoma: a Report of the Current Literature

Authors: Leandro Blas, Javier Roberti, Jorgelina Petroni, Liliana Reniero, Federico Cicora

Published in: Current Urology Reports | Issue 1/2019

Abstract

Purpose of the Review

We present an updated report of renal medullary carcinoma (RMC), a rare and aggressive condition.

Recent Findings

There is a majority of male patients, of African descent, in the second or third decade of life. In differential diagnosis, other tumors, such as malignant rhabdoid tumor (MRT), vinculin-anaplastic lymphoma kinase (VCL-ALK) translocation renal cell carcinoma, and collecting duct carcinoma, may present difficulties. Abnormalities of tumor suppressor gene SMARCB1 have been found in RMC. Reported symptoms were hematuria, pain, weight loss, respiratory distress, palpable mass, cough, and fever. Most patients present with metastases at diagnosis. There is no definite recommended treatment, and protocols are extrapolated from other malignancies, with nephrectomy and systemic therapies being most frequently used. Response to treatment and prognosis remain very poor.

Summary

RMC is a rare and aggressive tumor. Definitive diagnosis requires histological assessment and the presence of sickle-cell hemoglobinopathies.

Lee JS, Sanchez TR, Wootton-Gorges S. Malignant renal tumors in children. J Kidney Cancer VHL. 2015;2(3):84–9. https://doi.org/10.15586/jkcvhl.2015.29.CrossRefPubMedPubMedCentral

•• Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017;120(6):782–92. https://doi.org/10.1111/bju.13705 Large and Current Case Series of RMC.CrossRefPubMed

• Davis C, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11 First report of the condition.CrossRef

Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015;62(10):1694–9. https://doi.org/10.1002/pbc.25592.CrossRefPubMed

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798–805. https://doi.org/10.1016/j.eururo.2005.11.035.CrossRefPubMed

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, et al. Renal medullary carcinoma: establishing standards in practice. J Oncol Pract. 2017;13(7):414–21. https://doi.org/10.1200/JOP.2017.020909.CrossRefPubMedPubMedCentral

Di Stefano RF, Buttigliero C, De Luca E, Reale ML, Pisano C, Leone G, et al. Metastatic renal medullary carcinoma treated with immune checkpoint inhibitor: case report and literature review. Clin Genitourin Cancer. 2018. https://doi.org/10.1016/j.clgc.2018.07.011.

Carden MA, Perdahl-Wallace E, Greenberg J, McCarty JM. Autologous stem-cell transplant for metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2018;65(9):e27267. https://doi.org/10.1002/pbc.27267.CrossRefPubMed

Lai JZ, Lai HH, Cao D. Renal cell carcinoma, unclassified with medullary phenotype and synchronous renal clear cell carcinoma present in a patient with no sickle cell trait/disease: diagnostic and therapeutic challenges. Anticancer Res. 2018;38(6):3757–61. https://doi.org/10.21873/anticanres.12657.CrossRefPubMed

10.

Goenaga-Vazquez Y, Colon G, Barrios N, Correa M. Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition. CEN Case Rep. 2018;7(1):121–6. https://doi.org/10.1007/s13730-018-0308-3.CrossRefPubMedPubMedCentral

11.

Ahmad HR, Faruk JA, Bugaje MA, Solomon A, Samaila MOA, Akuse RM. Sarcomatoid renal cell carcinoma in an adolescent with sickle cell anaemia. Case Rep Oncol Med. 2017;2017:2129450. https://doi.org/10.1155/2017/2129450.CrossRefPubMedPubMedCentral

12.

Heng DYC. Renal medullary carcinoma. J Oncol Pract. 2017;13(7):422–3. https://doi.org/10.1200/jop.2017.023812.CrossRefPubMed

13.

Ibilibor C, Medway A, Nelius T. Renal medullary carcinoma with an ophthalmic metastasis. Urol Ann. 2017;9(2):184–7. https://doi.org/10.4103/0974-7796.204184.CrossRefPubMedPubMedCentral

14.

Caliskan S, Gokce AM, Gumrukcu G, Onenerk M. Renal medullary carcinoma; a rare entity. Iran J Med Sci. 2017;42(2):215–8.PubMedPubMedCentral

15.

Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, et al. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. J Immunother Cancer. 2017;5:1. https://doi.org/10.1186/s40425-016-0206-1.CrossRefPubMedPubMedCentral

16.

Kalavar MR, Ali S, Safarpour D, Kunnakkat SD. Renal medullary carcinoma with an aggressive clinical course: a case report and review of the literature. Case Rep Oncol. 2017;10(1):1–7. https://doi.org/10.1159/000455007.CrossRefPubMedPubMedCentral

17.

Colombo P, Smith SC, Massa S, Renne SL, Brambilla S, Peschechera R, et al. Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait. Urol Case Rep. 2015;3(6):215–8. https://doi.org/10.1016/j.eucr.2015.07.011.CrossRefPubMedPubMedCentral

18.

Batra S. Is there a role for antiangiogenic therapy in renal medullary carcinoma? Pediatr Blood Cancer. 2016;63(4):746–7. https://doi.org/10.1002/pbc.25832.CrossRefPubMed

19.

Rabener MJ, Howell C. Chest discomfort in a patient with cancer. JAAPA: Official Journal of the American Academy of Physician Assistants. 2015;28(6):43–4, 466. https://doi.org/10.1097/01.JAA.0000464279.28870.3b.CrossRef

20.

Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, et al. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther. 2015;16(1):28–33. https://doi.org/10.4161/15384047.2014.972843.CrossRefPubMedPubMedCentral

21.

Mast Vilaseca R, Pons EA. Renal medullary carcinoma in a young white adult without sickle cell trait or disease. Australas Radiol. 2015;57(4):361–3. https://doi.org/10.1016/j.rx.2014.09.003.CrossRef

22.

Levi Sandri GB, Spoletini G, Lai Q, Mennini G, Rossi M. Cystic presentation of a renal medullary carcinoma in a young woman. Urologia. 2015;82(2):124–6. https://doi.org/10.5301/uro.5000097.CrossRefPubMed

23.

Tripathy K, Misra A, Dash K. Cytodiagnosis of renal medullary carcinoma: report of a case with immunocytochemistry. Cytopathology. 2015;26(5):328–30. https://doi.org/10.1111/cyt.12225.CrossRefPubMed

24.

Amjad AI, Ali H, Appleman LJ, Maranchie J, Jackman S, Parwani A, et al. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Case Rep Oncol Med. 2014;2014:615895. https://doi.org/10.1155/2014/615895.CrossRefPubMedPubMedCentral

25.

Shetty A, Matrana MR. Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014;14(2):270–5.PubMedPubMedCentral

26.

Daher P, Bourgi A, Riachy E, Khoury A, Rehayem C, Sader-Ghorra C. Renal medullary carcinoma in a white adolescent with sickle cell trait. J Pediatr Hematol Oncol. 2014;36(5):e285–9. https://doi.org/10.1097/mph.0000000000000118.CrossRefPubMed

27.

Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park, NY). 2013;27(9):893, 6, 8.

28.

Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 2013;5(3):e44. https://doi.org/10.4081/rt.2013.e44.CrossRefPubMedPubMedCentral

29.

Marsh A, Golden C, Hoppe C, Quirolo K, Vichinsky E. Renal medullary carcinoma in an adolescent with sickle cell anemia. Pediatr Blood Cancer. 2014;61(3):567. https://doi.org/10.1002/pbc.24795.CrossRefPubMed

30.

Anne M, Sammartino D, Chaudhary S, Bhuiya T, Mehrotra B. Renal medullary carcinoma masquerading as bilateral breast carcinoma category: case report. World J Oncol. 2013;4(3):169–72. https://doi.org/10.4021/wjon676w.CrossRefPubMedPubMedCentral

31.

Sodji Q, Klein K, Sravan K, Parikh J. Predictive role of PD-L1 expression in the response of renal medullary carcinoma to PD-1 inhibition. J Immunother Cancer. 2017;5(1):62. https://doi.org/10.1186/s40425-017-0267-9.CrossRefPubMedPubMedCentral

32.

Carter SA, Walker AN. Renal medullary carcinoma and sickle cell trait: a push for early diagnosis and intervention report of two cases. J Natl Med Assoc. 2017;109(1):63–5. https://doi.org/10.1016/j.jnma.2016.08.006.CrossRefPubMed

33.

Carden MA, Smith S, Meany H, Yin H, Alazraki A, Rapkin LB. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases. Pediatr Blood Cancer. 2017;64(7). https://doi.org/10.1002/pbc.26402.

34.

Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37(3):368–74.CrossRef

35.

Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the children's oncology group study AREN03B2. Cancer. 2015;121(14):2457–64. https://doi.org/10.1002/cncr.29368.CrossRefPubMedPubMedCentral

36.

Shi Z, Zhuang Q, You R, Li Y, Li J, Cao D. Clinical and computed tomography imaging features of renal medullary carcinoma: a report of six cases. Oncol Lett. 2016;11(1):261–6. https://doi.org/10.3892/ol.2015.3891.CrossRefPubMed

37.

Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, et al. Imaging of renal medullary carcinoma in children and young adults: a report from the children's oncology group. Pediatr Radiol. 2017;47(12):1615–21. https://doi.org/10.1007/s00247-017-3926-6.CrossRefPubMedPubMedCentral

38.

Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, et al. Genomic characterization of renal medullary carcinoma and treatment outcomes. Clin Genitourin Cancer. 2017;15(6):e987–e94. https://doi.org/10.1016/j.clgc.2017.04.012.CrossRefPubMedPubMedCentral

39.

•• Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ et al. Renal medullary carcinoma: a national analysis of 159 patients. Pediatr Blood Cancer. 2017;64(11). https://doi.org/10.1002/pbc.26609. Large national analysis of RMC patients.

40.

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279–92. https://doi.org/10.1097/pas.0000000000001000.CrossRefPubMed

41.

Gebreselassie S, Simmons MN, Montague DK. Genitourinary manifestations of sickle cell disease. Cleve Clin J Med. 2015;82(10):679–83. https://doi.org/10.3949/ccjm.82a.14029.CrossRefPubMed

42.

Pawel BR. SMARCB1-deficient tumors of childhood: a practical guide. Pediatr Dev Pathol. 2018;21(1):6–28. https://doi.org/10.1177/1093526617749671.CrossRefPubMed

43.

Jarzembowski JA. Pediatric renal and genitourinary tract tumors and the contributions of Dr. Louis "Pepper" Dehner therewith. Semin Diagn Pathol. 2016;33(6):419–26. https://doi.org/10.1053/j.semdp.2016.08.005.CrossRefPubMed

44.

Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol. 2014;21(6):394–410. https://doi.org/10.1097/PAP.0000000000000038.CrossRefPubMed

45.

Fleming S. Distal nephron neoplasms. Semin Diagn Pathol. 2015;32(2):114–23. https://doi.org/10.1053/j.semdp.2015.02.004.CrossRefPubMed

46.

Chung EM, Lattin GE Jr, Fagen KE, Kim AM, Pavio MA, Fehringer AJ, et al. Renal tumors of childhood: radiologic-pathologic correlation part 2. The 2nd decade: from the radiologic pathology archives. Radiographics. 2017;37(5):1538–58. https://doi.org/10.1148/rg.2017160189.CrossRefPubMedPubMedCentral

47.

Anazoeze M, Najibah G, Garba U, Shehu A, Florence F, Abdulaziz H, et al. Is renal medullary carcinoma the seventh nephropathy in sickle cell disease? A multi-center Nigerian survey. Afr Health Sci. 2016;16(2):490–6. https://doi.org/10.4314/ahs.v16i2.17.CrossRefPubMedPubMedCentral

48.

Kalimuthu SN, Chetty R. Gene of the month: SMARCB1. J Clin Pathol. 2016;69(6):484–9. https://doi.org/10.1136/jclinpath-2016-203650.CrossRefPubMedPubMedCentral

49.

• Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas. Eur Urol. 2016;69(6):1055–61. https://doi.org/10.1016/j.eururo.2015.09.027 Paper on the explanatory model of genetic abnormalities in RMC. CrossRefPubMed

50.

• Msaouel P, Tannir NM, Walker CL. A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma. Clin Cancer Res. 2018;24(9):2044–9. https://doi.org/10.1158/1078-0432.Ccr-17-3296 Proposed model on RMC. CrossRefPubMed

51.

Amin MB, Smith SC, Agaimy A, Argani P, Compérat EM, Delahunt B, et al. Collecting duct carcinoma versus renal medullary carcinoma. Am J Surg Pathol. 2014;38(7):871–4. https://doi.org/10.1097/pas.0000000000000222.CrossRefPubMed

52.

Seo AN, Yoon G, Ro JY. Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas. Adv Anat Pathol. 2017;24(2):65–77. https://doi.org/10.1097/PAP.0000000000000138.CrossRefPubMed

53.

Gupta S, Kang HC, Ganeshan DM, Bathala TK, Kundra V. Diagnostic approach to hereditary renal cell carcinoma. AJR Am J Roentgenol. 2015;204(5):1031–41. https://doi.org/10.2214/AJR.14.13514.CrossRefPubMed

54.

Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015;9(3–4):E172–7. https://doi.org/10.5489/cuaj.2373.CrossRefPubMedPubMedCentral

Title: Renal Medullary Carcinoma: a Report of the Current Literature
Authors: Leandro Blas
Javier Roberti
Jorgelina Petroni
Liliana Reniero
Federico Cicora
Publication date: 01-01-2019
Publisher: Springer US
Keywords: Nephrectomy
Nephrectomy
Hematuria
Nephrectomy
Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: Current Urology Reports / Issue 1/2019
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-019-0865-9

At a glance: The STEP trials

Springer Medicine

Renal Medullary Carcinoma: a Report of the Current Literature

Abstract

Purpose of the Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2019

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

Use of Mannitol for Ischemia Reperfusion Injury in Kidney Transplant and Partial Nephrectomies—Review of Literature

Surgical Treatment of Completely Endophytic Renal Tumor: a Systematic Review

Vascular Injury During Urologic Surgery: Somebody Call My Mother

Imaging of Unusual Renal Tumors